



Curetis to Hold Annual General Shareholders' Meeting on June 23, 2017

- Company nominates Dr Nils Clausnitzer for election into its Supervisory Board

Amsterdam, the Netherlands, and Holzgerlingen, Germany, May 8, 2017 - Curetis N.V. (the "**Company**") and, together with Curetis GmbH, "**Curetis**"), a developer of next-level molecular diagnostic solutions, today published the invitation to its annual general shareholders' meeting ("AGM").

Curetis will hold its AGM on June 23, 2017, at Steigenberger Hotel, Stationsplein Zuid - West 951, 1117 CE Schiphol - Oost/Amsterdam, the Netherlands. The meeting is scheduled to commence at 13:30 hours CEST; local registration starts at 13:00 hours CEST.

In addition, Curetis will be offering electronic pre-voting starting on Saturday, May 27, 2017, at 08:00 hours CEST at www.abnamro.com/evoting.

A copy of the convening notice for the AGM, including a description of the formalities to participate in the AGM, is available at <http://www.curetis.com/en/investors/share-information/annual-general-meeting.html>.

Primary resolutions on the agenda of the AGM relate to changes in the Supervisory Board, specifically the proposed election of Dr Nils Clausnitzer (Senior Vice President and President, EMEA-APAC Lab and Distribution Services of VWR International llc/ VWR GmbH) as a new Supervisory Board member for a three-year term until the ordinary general shareholder meeting 2020, and the re-election of Dr Holger Reithinger and Dr Rudy Dekeyser for another one-year term, respectively.

###

Disclaimer

CAUTION - Investigational device. Limited by Federal (or United States) law to investigational use. The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on the Curetis Unyvero technology is currently available for sale in the United States of America or Canada. The analytical and clinical performance characteristics of any Curetis Unyvero product which may be sold at some future point in time in the U.S. have not yet been established.

###

About Curetis

Founded in 2007, Curetis is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis enable rapid multi-parameter pathogen and antibiotic resistance marker detection in only a few hours, a process that today can take up to days or even weeks with other techniques.

To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and Euronext Brussels and private equity funds of over EUR 63.5 million. Furthermore, Curetis has entered into a debt financing facility with EIB for up to EUR 25 million. The company is based in Holzgerlingen near Stuttgart, Germany. Curetis collaborates with Heraeus Medical, pharmaceutical companies, and has entered into several international distribution agreements covering many countries across Europe, the Middle East and Asia.

In 2017, Curetis established Ares Genetics GmbH, a wholly-owned subsidiary of Curetis GmbH in Vienna, Austria. Ares Genetics is dedicated to maximizing the R&D and related scientific and business opportunities of the GEAR assets acquired in 2016 for the entire Curetis Group.

For further information, please visit www.curetis.com.

Legal Disclaimer

This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in Curetis.

The information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.

This press release includes statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “anticipates”, “expects”, “intends”, “may”, “will”, or “should”, and include statements Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Curetis’ actual results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

Contact details

Curetis
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
pr@curetis.com or ir@curetis.com
www.curetis.com - www.unyvero.com

International Media & Investor Inquiries

akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners

info@akampion.com

Tel. +49 40 88 16 59 64

Tel. +49 30 23 63 27 68

U.S. Media & Investor Inquiries

The Ruth Group

Lee Roth

lroth@theruthgroup.com

Tel. +1 646 536 7012

--

Elena Christina Billig

Investor Relations Manager

Curetis GmbH

Max-Eyth-Straße 42

71088 Holzgerlingen

Tel: +49 (0) 7031 9231961

Mobile: +49 (0) 1786352386

Fax: +49 (0) 7031 49195-19

<http://www.curetis.com/>

<mailto:elena.billig@curetis.com>

Geschäftsführer: Oliver Schacht, PhD, Andreas Boos, Johannes Bacher, Dr. Achim Plum, Heiko Schorr
Amtsgericht Stuttgart HRB 756134

This e-mail and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom it is addressed. If you are not the intended recipient or have received this e-mail in error, please notify the sender immediately and destroy this e-mail. Any unauthorised dissemination or copying of this email or its attachments, and any use or disclosure of any information contained therein, is strictly prohibited and may be illegal.